Increase in Research and Development Expenses for Focus Areas and Doubling of New-Business Investment
First written in FY2016. 20 of 31 entries say "Restated". Latest entry: FY2026.
56 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses for the fiscal year were ¥28,423 million, up 11.7% from the previous fiscal year,」
R&D expenses were increased 11.7% year on year to ¥28.423 billion. Development is under way in areas including CPO, 1,000-km-class optical networks, high-voltage products for electric vehicles, wireless power transmission, green LP gas and nuclear fusion. - 2026-05-12AchievedEarnings
「Growth rate of R&D expenses for new businesses (FY2021 baseline) 125% 156%」
The growth rate of R&D expenses for new businesses in FY2025 was 156%, versus the target of 125%. - FY2025AdvancedAnnual report
「R&D expenses for the fiscal year were ¥25,449 million, up 3.7% from the previous fiscal year,」
R&D expenses were increased 3.7% year on year to ¥25.449 billion. Development is under way in areas including CPO, hollow-core fiber, high-voltage automotive components, heat-dissipation products for data centers, green LP gas and nuclear fusion. - FY2024AdvancedAnnual report
「R&D expenses for the fiscal year were set at ¥24,539 million, up 5.2% from the previous fiscal year, and the main results of each segment were as follows.」
R&D expenses were increased 5.2% year on year to ¥24.539 billion. Development is under way in areas including optoelectronic integration, electric vehicles, energy storage batteries, heat-dissipation products related to generative AI, nuclear fusion and green LP gas. - FY2024-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥12.4 billion. There were no material changes during the cumulative second quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in R&D activities related to the focus areas and the creation of new businesses, and disclosed first-half R&D expenses of ¥12.4 billion. - FY2024-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥6.4 billion. There were no material changes during the cumulative first quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in research and development activities and disclosed cumulative first-quarter R&D expenses of ¥6.4 billion. - FY2023AdvancedAnnual report
「R&D expenses for the fiscal year were set at ¥23,324 million, up 12.3% from the previous fiscal year.」
R&D expenses for the focus areas and the creation of new businesses were increased 12.3% year on year to ¥23.324 billion. - FY2023-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥17.9 billion. There were no material changes during the cumulative third quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and disclosed cumulative third-quarter R&D expenses of ¥17.9 billion. - FY2023-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥11.8 billion. There were no material changes during the cumulative second quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in research and development activities and disclosed cumulative R&D expenses of ¥11.8 billion. - FY2023-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥5.9 billion. There were no material changes during the cumulative first quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and disclosed cumulative first-quarter R&D expenses of ¥5.9 billion. - FY2022AdvancedAnnual report
「R&D expenses for the fiscal year were set at ¥20,761 million, up 2.7% from the previous fiscal year.」
R&D continued in the focus areas and for the creation of new businesses, and R&D expenses were increased 2.7% year on year to ¥20.761 billion. - FY2022-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥15.6 billion. There were no material changes during the cumulative third quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and disclosed cumulative third-quarter R&D expenses of ¥15.6 billion. - FY2022-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥5.0 billion. There were no material changes during the cumulative first quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in research and development activities and disclosed cumulative first-quarter R&D expenses of ¥5.0 billion. - FY2021Decrease in R&D expensesAnnual report
「R&D expenses for the fiscal year were set at ¥20,217 million, down 6.6% from the previous fiscal year.」
Although R&D continued in the focus areas and for the creation of new businesses, R&D expenses fell 6.6% year on year to ¥20.217 billion. - FY2021-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥15.5 billion. There were no material changes during the cumulative third quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and disclosed cumulative third-quarter R&D expenses of ¥15.5 billion. - FY2021-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥10.4 billion. There were no material changes during the cumulative second quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in research and development activities and disclosed cumulative second-quarter R&D expenses of ¥10.4 billion. - FY2021-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥5.2 billion. There were no material changes during the cumulative first quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in research and development activities and disclosed R&D expenses of ¥5.2 billion for the cumulative first quarter. - FY2020AdvancedAnnual report
「R&D expenses for the fiscal year were set at ¥21,650 million, up 2.4% from the previous fiscal year, to strengthen the focus areas and promote the creation of new businesses.」
R&D expenses were increased 2.4% year on year to ¥21.650 billion to strengthen the focus areas and promote the creation of new businesses. - FY2020-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥16.5 billion. There were no material changes during the cumulative third quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in research and development activities and disclosed R&D expenses of ¥16.5 billion for the cumulative third quarter. - FY2020-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥10.9 billion. There were no material changes during the cumulative second quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It reconfirmed that there had been no material changes in research and development activities and disclosed R&D expenses of ¥10.9 billion for the cumulative second quarter. - FY2020-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥5.4 billion. There were no material changes during the cumulative first quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and disclosed R&D expenses of ¥5.4 billion for the cumulative first quarter. - FY2019AdvancedAnnual report
「R&D expenses for the fiscal year were set at ¥21,141 million, up 8.2% from the previous fiscal year, to strengthen the focus areas and promote the creation of new businesses.」
R&D expenses were increased 8.2% year on year to ¥21.141 billion to strengthen the focus areas and promote the creation of new businesses. - FY2019-Q3RestatedAnnual report
「R&D expenses for the cumulative third quarter were ¥15.9 billion. There were no material changes during the cumulative third quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and reported R&D expenses of ¥15.9 billion for the cumulative third quarter. - FY2019-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter were ¥10.3 billion. There were no material changes during the cumulative second quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and reported R&D expenses of ¥10.3 billion for the cumulative second quarter. - FY2019-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter were ¥5.0 billion. There were no material changes during the cumulative first quarter in the status of the Group's research and development activities from the information provided in the annual securities report for the previous fiscal year.」
It stated that there had been no material changes in research and development activities and reported R&D expenses of ¥5.0 billion for the cumulative first quarter. - FY2018AdvancedAnnual report
「R&D expenses for the fiscal year were set at ¥19,533 million, up 11.9% from the previous fiscal year, to strengthen the focus areas.」
R&D expenses were increased 11.9% year on year to ¥19.533 billion to strengthen the focus areas. - FY2018-Q2RestatedAnnual report
「There were no material changes in the status of the Group’s R&D activities during the six months ended June 30, XXXX.」
It was reconfirmed that there had been no material changes in the status of research and development activities. R&D expenses were ¥9.4 billion. - FY2018-Q1RestatedAnnual report
「R&D expenses for the cumulative first quarter ended were ¥4.6 billion. There were no material changes in the status of the Group's R&D activities during the cumulative first quarter ended.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥4.6 billion for the first quarter. - FY2017RestatedAnnual report
「Under the medium-term management plan "Furukawa G Plan 2020," which began in FY2016, we will give priority to allocating management resources to capital investment and R&D aimed at increasing profit in the Group's priority business fields, infrastructure and automotive markets, which support sustainable growth, and creating new businesses.」
The company continues to prioritize the allocation of resources to capital investment and R&D in infrastructure, automotive and new businesses. - FY2017-Q2RestatedAnnual report
「R&D expenses for the cumulative second quarter ended were ¥8.4 billion. There were no material changes in the status of the Group's R&D activities during the cumulative second quarter ended.」
The company stated that there were no material changes in its R&D activities and reported R&D expenses of ¥8.4 billion for the cumulative period. - FY2016First statedAnnual report
「We will increase annual R&D spending on products for our priority infrastructure and automotive markets by approximately 20% over the next 5 years compared with FY2015, expand our business in these fields, and commercialize new technologies such as peripheral-monitoring radar, a sensing technology supporting advanced driver-assistance systems. In addition, we will double annual investment and R&D spending by FY2020 compared with FY2015 in fields expected to achieve future market growth, including medical devices, where we expect to enter with pathogen testing equipment using our fluorescent silica nanoparticle technology and catheter guidewires using our resin molding technology, thereby promoting the development of new businesses.」
The company set numerical targets of increasing R&D spending for infrastructure and automotive products by approximately 20% over 5 years and doubling investment and R&D spending in growth fields by FY2020.